However, about 30% to 40% of those with IgA nephropathy develop kidney failure 20 to 30 years after symptom onset. Early ...

The trial assessed the safety and efficacy of the therapy against placebo in patients with IgAN. Subjects treated with the therapy in conjunction with a RAS inhibitor experienced a reduction of 36 ...

The new Oxford classification of IgA nephropathy has been developed as a pathological classification system to reliably predict the risk of disease progression. Future studies need to demonstrate ...

“The European Commission’s standard approval of FILSPARI is a meaningful step forward for people living with IgA nephropathy across Europe,” said Jula Inrig, M.D., chief medical officer of ...